A new protein targeted treatment for B-cell lymphoma
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Finding why immunotherapy doesn't work for some children with sarcoma tumours.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.